D

Dynavax Technologies Corp
D

DVAX

11.360
USD
0.21
(1.88%)
مغلق
حجم التداول
24,030
الربح لكل سهم
0
العائد الربحي
-
P/E
-23
حجم السوق
1,364,116,184
أصول ذات صلة
A
AEMD
-0.03000
(-2.21%)
1.33000 USD
B
BCRX
0.00000
(0.00%)
8.55500 USD
H
HRTX
0.00000
(0.00%)
1.90500 USD
L
LPCN
0.07500
(2.23%)
3.44000 USD
M
MNKD
-0.02500
(-0.61%)
4.05000 USD
S
SNDX
-0.39000
(-3.90%)
9.62000 USD
المزيد
الأخبار المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.